203 related articles for article (PubMed ID: 26381898)
1. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach.
Soudry-Kochavi L; Naraykin N; Nassar T; Benita S
J Control Release; 2015 Nov; 217():202-10. PubMed ID: 26381898
[TBL] [Abstract][Full Text] [Related]
2. The use of low molecular weight protamine to enhance oral absorption of exenatide.
Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y
Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739
[TBL] [Abstract][Full Text] [Related]
3. An approach for half-life extension and activity preservation of an anti-diabetic peptide drug based on genetic fusion with an albumin-binding aptide.
Kim D; Jeon H; Ahn S; Choi WI; Kim S; Jon S
J Control Release; 2017 Jun; 256():114-120. PubMed ID: 28457895
[TBL] [Abstract][Full Text] [Related]
4. Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin.
Shan W; Zhu X; Liu M; Li L; Zhong J; Sun W; Zhang Z; Huang Y
ACS Nano; 2015 Mar; 9(3):2345-56. PubMed ID: 25658958
[TBL] [Abstract][Full Text] [Related]
5. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation.
Zhang Y; Wu X; Meng L; Zhang Y; Ai R; Qi N; He H; Xu H; Tang X
Int J Pharm; 2012 Oct; 436(1-2):341-50. PubMed ID: 22766443
[TBL] [Abstract][Full Text] [Related]
6. The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.
Li X; Wang C; Liang R; Sun F; Shi Y; Wang A; Liu W; Sun K; Li Y
Pharm Res; 2015 Mar; 32(3):1017-27. PubMed ID: 25270570
[TBL] [Abstract][Full Text] [Related]
7. Sol-gel transition of nanoparticles/polymer mixtures for sustained delivery of exenatide to treat type 2 diabetes mellitus.
Oh KS; Kim JY; Yoon BD; Lee M; Kim H; Kim M; Seo JH; Yuk SH
Eur J Pharm Biopharm; 2014 Nov; 88(3):664-9. PubMed ID: 25152212
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption.
Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Chu L; Yan X; Zhao M; Zhang X; Mu H; Sun K
Mol Pharm; 2019 Feb; 16(2):518-532. PubMed ID: 30601014
[TBL] [Abstract][Full Text] [Related]
9. Biological activity of AC3174, a peptide analog of exendin-4.
Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
[TBL] [Abstract][Full Text] [Related]
10. Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery.
Xu B; Zhang W; Chen Y; Xu Y; Wang B; Zong L
Int J Biol Macromol; 2018 Jul; 113():534-542. PubMed ID: 29408613
[TBL] [Abstract][Full Text] [Related]
11. Oral delivery system for low molecular weight protamine-dextran-poly(lactic-co-glycolic acid) carrying exenatide to overcome the mucus barrier and improve intestinal targeting efficiency.
Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Zhang X; Sun K
Nanomedicine (Lond); 2019 Apr; 14(8):989-1009. PubMed ID: 31088322
[No Abstract] [Full Text] [Related]
12. Combination therapy via oral co-administration of insulin- and exendin-4-loaded nanoparticles to treat type 2 diabetic rats undergoing OGTT.
Chuang EY; Nguyen GT; Su FY; Lin KJ; Chen CT; Mi FL; Yen TC; Juang JH; Sung HW
Biomaterials; 2013 Oct; 34(32):7994-8001. PubMed ID: 23891516
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamical effects of orally administered exenatide nanoparticles embedded in gastro-resistant microparticles.
Soudry-Kochavi L; Naraykin N; Di Paola R; Gugliandolo E; Peritore A; Cuzzocrea S; Ziv E; Nassar T; Benita S
Eur J Pharm Biopharm; 2018 Dec; 133():214-223. PubMed ID: 30342089
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration.
Gedulin BR; Smith PA; Jodka CM; Chen K; Bhavsar S; Nielsen LL; Parkes DG; Young AA
Int J Pharm; 2008 May; 356(1-2):231-8. PubMed ID: 18291606
[TBL] [Abstract][Full Text] [Related]
15. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles.
Chalasani KB; Russell-Jones GJ; Jain AK; Diwan PV; Jain SK
J Control Release; 2007 Sep; 122(2):141-50. PubMed ID: 17707540
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo sustained release of exenatide from vesicular phospholipid gels for type II diabetes.
Zhang Y; Zhong Y; Hu M; Xiang N; Fu Y; Gong T; Zhang Z
Drug Dev Ind Pharm; 2016; 42(7):1042-9. PubMed ID: 26558908
[TBL] [Abstract][Full Text] [Related]
17. Self-nanoemulsifying drug delivery systems for oral insulin delivery: in vitro and in vivo evaluations of enteric coating and drug loading.
Li P; Tan A; Prestidge CA; Nielsen HM; Müllertz A
Int J Pharm; 2014 Dec; 477(1-2):390-8. PubMed ID: 25455781
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic uptake of the lipidated and non-lipidated GLP-1 agonists liraglutide and exenatide is similar in rats.
Reddiar SB; Abdallah M; Styles IK; Müllertz OO; Trevaskis NL
Eur J Pharm Biopharm; 2024 Jul; 200():114339. PubMed ID: 38789061
[TBL] [Abstract][Full Text] [Related]
19. Eudragit S100-Coated Chitosan Nanoparticles Co-loading Tat for Enhanced Oral Colon Absorption of Insulin.
Chen S; Guo F; Deng T; Zhu S; Liu W; Zhong H; Yu H; Luo R; Deng Z
AAPS PharmSciTech; 2017 May; 18(4):1277-1287. PubMed ID: 27480441
[TBL] [Abstract][Full Text] [Related]
20. Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.
Chen C; Zhu X; Dou Y; Xu J; Zhang J; Fan T; Du J; Liu K; Deng Y; Zhao L; Huang Y
J Biomed Nanotechnol; 2015 May; 11(5):865-76. PubMed ID: 26349398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
